AZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatmentAstraZeneca and MSD’s Lynparza has scored its second Phase 3 win in the space of a week, this Share XAZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatmenthttps://pharmaphorum.com/news/az-msd-parp-inhibitor-ovarian-cancer/
AstraZeneca ends another Calquence trial earlyFor the second time in the space of a month AstraZeneca has stopped a trial of its chronic Share XAstraZeneca ends another Calquence trial earlyhttps://pharmaphorum.com/news/astrazeneca-ends-another-calquence-trial-early/
AstraZeneca ends leukaemia trial early after promising resultsAstraZeneca has said that it will stop a Phase III trial of its chronic lymphocytic leukaemia drug Calquence Share XAstraZeneca ends leukaemia trial early after promising resultshttps://pharmaphorum.com/news/astrazeneca-ends-leukaemia-trial-early-after-promising-results/
